Blood pressure reduction in the metabolic syndrome and type 2 diabetes: Current concepts

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 6, 2005, Pages 320-324

  Schachter, Michael ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Combination therapy; Diabetes; Hypertension; Metabolic syndrome; Nephrophathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; NEBIVOLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW;

EID: 30544439553     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050060401     Document Type: Review

References (32)

1. Kahn R, Ferrannini E, Buse J, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28;2289-304.
2. Zimmet PZ, Alberti G. The metabolic syndrome; perhaps an etiologic mystery but far from a myth - where does the International Diabetes Federation stand? http://www.medscape.com/viewarticle/514211
3. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
4. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-17.
5. Colhoun HIM, Dong W, Barakat MT, Mather HM, Poulter NR. The scope for cardiovascular disease risk intervention among people with diabetes mellitus in England: a population based analysis from the Health Surveys for England 1991-94. Diabet Med 1999;16:35-40.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
8. Curb JD, Pressel SL, Cutler JA et al. Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.
9. Davis BR, Langford HG, Blaufox MID, Curb JD, Polk BF, Shulman NB. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation 1987;75:340-6.
10. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and hypertension. N Engl J Med 1999;230:677-84.
11. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimised Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
12. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effects of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-B64.
13. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.
14. Bestermann W, Houston MC, Basile J et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005;329:292-305.
15. Ravid M, Rachmani R. Cardiovascular protection in patients with type 2 diabetes mellitus: Considerations about the tightness of blood pressure control and the choice of treatment. Eur J Int Med 2005;16:154-9.
16. Choi KL, Bakris GL. Hypertension treatment guidelines: practical implications. Semin Nephrol 2005;25:198-209.
17. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on CV events in highrisk patients. N Engl J Med 2000;342:145-53.
19. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research droup. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
21. Deedwania PC. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin 2005; 23:139-52.
22. Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005;18:112S-119S.
23. Kopyt NP. Slowing progression along the renal disease spectrum. J Am Osteopath Assoc 2005;105:207-15.
24. Waley-Connell A, Sowers JR. Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII. Endocrinol Metab Clin North Am 2005;34:63-75.
25. Welsh L, Ferro A. Drug treatment of essential hypertension: the case for initial combination therapy. In J Clin Pract 2004;58:956-63.
26. Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Human Hypertens 2003;17:81-6.
27. Laragh JH. Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int 1993;44:1163-75.
28. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists. Effects on cardiorenal risk in hypertensive patients. Hypertension 2005;46:637-42.
29. Carlberg B, Samuellsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9.
30. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005;42:S17-S25.
31. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amloclipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
32. Abuissa H, Jones PG, Marson SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-6.